Pacira Story

<div class='circular--portrait' style='background:#347AFC;color: #ffffff;font-size:4em;'>PP</div>
PCRX -- USA Stock  

USD 60.12  0.73  1.23%

Today's article will break down Pacira Pharmaceuticals. We will evaluate why we are still confident in anticipation of a recovery. Pacira Pharmaceuticals is at this time traded for 56.10. The entity has historical hype elasticity of 0.45. The average price elasticity to hype of competition is about -0.26. The firm is projected to increase in value after the next headline, with the price going to jump to 56.55. The current volatility of media hype impact on the company stock price is is way over 100 percent making price predictions on social media along less reliable. The price jump on the next news is estimated to be 0.8%, whereas the daily expected return is at this time at 0.52%. The volatility of related hype on Pacira Pharmaceuticals is about 721.54% with expected price after next announcement by competition of 55.84 Given the investment horizon of 30 days, the next projected press release will be in about 7 days.
Published over a month ago
View all stories for Pacira Pharmaceuticals | View All Stories
Should I exit my Pacira Pharmaceuticals (NASDAQ:PCRX) holdings?
This firm's average rating is Buy from 13 analysts. Our advice module provides unbiased recommendation that can be used to complement current average analyst sentiment on Pacira Pharmaceuticals. Our advice engine provides an advice for the company potential to grow from the perspective of an investor's risk tolerance and investing horizon. About 112.0% of the company shares are owned by institutional investors. Pacira Pharmaceuticals has Price/Earnings To Growth (PEG) ratio of 0.65. The entity had not issued any dividends in recent years.
The successful prediction of Pacira Pharmaceuticals stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Pacira Pharmaceuticals, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Pacira Pharmaceuticals based on Pacira Pharmaceuticals hews, social hype, general headline patterns, and widely used predictive technical indicators. We also calculate exposure to Pacira Pharmaceuticals's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Pacira Pharmaceuticals's related companies.

Use Technical Analysis to project Pacira expected Price

Pacira Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Pacira Pharmaceuticals technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Pacira Pharmaceuticals trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions. It is good to see analyst projects for Pacira Pharmaceuticals, but it might be worth checking our own buy vs. sell analysis

Exercise or conversion by Gary Pace of 70000 shares of Pacira Pharmaceuticals subject to Rule 16b-3

Legal trades by Pacira Pharmaceuticals insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Pacira insider trading alert for exercise of stock option (right to buy) by Gary Pace, the corporate stakeholder, on 29th of September 2020. This event was filed by Pacira Biosciences Inc with SEC on 2020-09-29. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

A Deeper Perspective

The company reported the previous year's revenue of 435.4 M. Net Loss for the year was (86 K) with profit before overhead, payroll, taxes, and interest of 242.19 M.
 2017 2018 2019 2020 (projected)
Receivables31.66 M38 M47.53 M51.28 M
Inventories41.41 M48.57 M58.3 M62.9 M

Deferred Revenue Breakdown

Pacira Pharmaceuticals Deferred Revenue yearly trend continues to be fairly stable with very little volatility. Deferred Revenue is likely to outpace its year average in 2020. Deferred Revenue usually refers to a component of Total Liabilities representing the carrying amount of consideration received or receivable on potential earnings that were not recognized as revenue; including sales; license fees; and royalties; but excluding interest income. Pacira Pharmaceuticals Deferred Revenue is fairly stable at the moment as compared to the past year. Pacira Pharmaceuticals reported Deferred Revenue of 91,800 in 2019
2012
2013
2014
2015
2016
2017
2019
2020
20124.69 Million
20134.22 Million
201410.93 Million
20159.51 Million
2016595,000
2017102,000
201991,800
202094,215.79

Momentum Analysis of Pacira Pharmaceuticals suggests possible reversal in September

The treynor ratio is down to 0.43 as of today. As of the 6th of August, Pacira Pharmaceuticals holds the Coefficient Of Variation of 634.47, semi deviation of 2.16, and Risk Adjusted Performance of 0.2588. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Pacira Pharmaceuticals, as well as the relationship between them. Put it differently, you can use this information to find out if the company will indeed mirror its model of past market data, or the prices will eventually revert. We were able to interpolate data for nineteen technical drivers for Pacira Pharmaceuticals, which can be compared to its competitors. Please check Pacira Pharmaceuticals mean deviation, information ratio, as well as the relationship between the Information Ratio and downside variance to decide if Pacira Pharmaceuticals is priced some-what accurately, providing market reflects its current price of 56.1 per share. Given that Pacira Pharmaceuticals has jensen alpha of 0.2779, we recommend you to check out Pacira Pharmaceuticals's recent market performance to make sure the company can sustain itself at a future point.

The Bottom Line

While some other firms within the drug manufacturers?specialty & generic industry are still a little expensive, even after the recent corrections, Pacira Pharmaceuticals may offer a potential longer-term growth to investors. While some investors may not share our view, we believe it may be a good time to increase your existing holdings in Pacira as the risk-reward trade off is appealing enough to hold a position. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Pacira Pharmaceuticals.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Pacira Pharmaceuticals. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com